Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PHX.AX
SellPharmX Technologies Limited · Healthcare · Australia · $59M · Avg Vol: $12K/d
22
StockRankGet insider-trade alerts
Q
43
V
27
M
34
P/E (TTM)
—
ROE
-5.9%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
PharmX Technologies Limited, together with its subsidiaries, operates as a technology and software development company in Australia.
FINANCIAL SUMMARY (AUD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 11.9M | 6.0M | 6.5M | 7.3M | -15.0% | 7.7M |
| EPS (AUD) | 0.00 | -0.00 | -0.00 | -0.00 | — | — |
| Shares | 596.8M | 597.4M | 598.5M | 598.5M | +0.3% | 666.1M |
| Debt | 0.3M | 32.0K | 0.2M | 0.9M | 40.0% | 0.7M |
| Equity | 23.2M | 22.2M | 16.0M | 15.9M | -11.8% | — |
| Op CF | 3.3M | 10.9M | 3.2M | -8.1M | -1.2% | 1.0M |
| Inv CF | -3.6M | -3.6M | 1.7M | -0.7M | — | — |
| Fin CF | -0.4M | -0.3M | -4.6M | -0.1M | — | — |
Loading 1Y...
PRICE (1Y)-9.1%
SMA 50SMA 200
Close
$0.0716
RSI (14)
50.0
52W High
$0.1433
From 52W High
0.5%
SCORE BREAKDOWN
Quality
43
ROIC
0.6%47.7
ROE
-5.9%40.5
GP/Assets
9.6%26.1
Op. Margin
-10.8%28.6
FCF/Assets
-6.5%33.8
Piotroski
550.3
Int. Cover
3.5x49.0
D/E Ratio
0.05x71.5
Current Ratio
3.68x61.4
Value
27
P/E (TTM)
—N/A
EV/EBITDA
-142.9x25.0
P/FCF
—N/A
P/B
3.7x37.5
P/S
8.3x30.7
Div Yield
—N/A
Momentum
34
52W High %
50%22.7
RS 6M
-15%49.3
SMA 50/200
0.90x35.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$59M
P/E (Forward)
—
Gross Margin
22.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PHX.AX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PHX.AX | PharmX Technologies Limited(you) | $59M | 22 | Sell |
| PKY.AX | Pathkey.AI Ltd | $57M | 21 | Sell |
| BB1.AX | BlinkLab Limited | $94M | 21 | Sell |
| ALC.AX | Alcidion Group Limited | $91M | 54 | Hold |
| AYA.AX | Artrya Limited | $533M | 35 | Hold |
| EIQ.AX | Echo IQ Limited | $812M | 28 | Sell |
| PTX.AX | Prescient Therapeutics Limited | $59M | 22 | Sell |
| LTP.AX | LTR Pharma Limited | $65M | 24 | Sell |
| CGS.AX | Cogstate Limited | $370M | 92 | Strong Buy |
| ALA.AX | Arovella Therapeutics Limited | $55M | 14 | Strong Sell |
Peer medians: ROE -27.4% · P/E 35.3x · Gross margin 61.9%